Fairmount Funds Management’s RayzeBio, Inc. Common Stock RYZB Stock Holding History

Fairmount Funds Management’s Portfolio RYZB Stock Details RYZB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,245,929	Closed	-$77.5M	–	17
2023 Q4	$77.5M	Buy	1,245,929 +24,025	+2%	+$597K	8.18%	5
2023 Q3	$27.1M	Buy	+1,221,904	New	+$25.7M	3.26%	12

Fairmount Funds Management's RYZB Position: Q1 2024 in Review

Fairmount Funds Management sold out of RayzeBio, Inc. Common Stock (RYZB) in Q1 2024, closing a stake of 1,245,929 shares — an estimated $77.5M sold.

Fairmount Funds Management first reported a position in RYZB in Q3 2023 and held it in 2 quarters. The position peaked at $77.5M in Q4 2023. 0 funds tracked by Wall St. Rank hold RYZB as of Q1 2024.

Fairmount Funds Management reported no remaining RayzeBio, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Fairmount Funds Management sold 1,245,929 RayzeBio, Inc. Common Stock shares in Q1 2024, an estimated $77.5M.
Fairmount Funds Management first reported a position in RayzeBio, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
Fairmount Funds Management's RayzeBio, Inc. Common Stock position peaked at $77.5M in Q4 2023.
0 funds tracked by Wall St. Rank held RayzeBio, Inc. Common Stock as of Q1 2024.

Based on Fairmount Funds Management's 13F filing for Q1 2024, filed 15 May 2024.